A randomized, double blind, double dummy, placebo controlled, four way crossover study to determine the effects of an H3 receptor antagonist (PF-03654746) on congestion following a nasal allergen challenge in subjects with seasonal allergic rhinitis

Trial Profile

A randomized, double blind, double dummy, placebo controlled, four way crossover study to determine the effects of an H3 receptor antagonist (PF-03654746) on congestion following a nasal allergen challenge in subjects with seasonal allergic rhinitis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs Fexofenadine; Fexofenadine/pseudoephedrine; PF 3654746
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Dec 2011 Results published in the Journal of Allergy and Clinical Immunology.
    • 22 Dec 2011 Primary endpoint 'Nasal-volume' has not been met.
    • 22 Dec 2011 Primary endpoint 'Nasal-parameters' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top